| Rank |
Status |
Study |
| 1 |
Recruiting
|
A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
| Conditions: |
Nocturia; Daytime Sleepiness |
| Intervention: |
Drug: Armodafinil 50 - 250 mg pills |
| Outcome Measures: |
Change in Epworth Sleepiness Scale; Clinical Global Impressions, change in severity of excessive daytime sleepiness (EDS); Number of naps; Number of minutes napped based on sleep diary |
|
| 2 |
Recruiting
|
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
| Condition: |
Fabry Disease |
| Intervention: |
Device: ResMed Apnea Link plus |
| Outcome Measure: |
Prevalence and type of sleep-related breathing disorder in Fabry patients. |
|
| 3 |
Recruiting
|
SleepTrackTXT Feasibility and Pilot Study
| Conditions: |
Fatigue; Sleepiness |
| Intervention: |
Behavioral: Text-message strategies |
| Outcome Measures: |
Self-Reported Fatigue at end of shift work; Self-reported perceptions of behaviors and beliefs about fatigue and sleepiness during shift work |
|
| 4 |
Recruiting
|
Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies
| Conditions: |
Parkinsonian Patients; Post-prandial Sleepiness; Orthostatic Hypotension |
| Interventions: |
Other: V1: HGPO + meal and V2: placebo + meal; Other: V1: placebo 75mg + meal and V2: HGPO 75mg + meal |
| Outcome Measures: |
Rate of patients presenting a "sleep onset"; rate of patients without arterial hypotension nor a sleep episode within 120 minutes after oral solution administration ;; rate of patients that show a sleep episode but without arterial hypotension within 120 minutes after oral solution administration ;; rate of patients that show arterial hypotension within 120 minutes after oral solution administration but not a sleep episode;; Occurrence of arterial hypotension and a sleep episode within 120 minutes following a standardized meal; Changes in intestine-pancreatic neuropeptides including incretins (GLP-1 - GIP) following an oral glucose load, placebo fructose load, or standardized meal - correlation with the post-prandial BP drop. |
|
| 5 |
Recruiting
|
Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children
| Conditions: |
Sleep Apnea, Obstructive; Sleep Apnea Syndromes; Child Behavior Disorders; Attention Deficit Disorder With Hyperactivity; Disorders of Excessive Somnolence |
| Interventions: |
Procedure: CPAP treatment; Other: No CPAP treatment |
| Outcome Measures: |
Neurobehavioral improvement after AT; Improvement in cognition after AT; Improvement in sleepiness and other sleep apnea symptoms after AT; Residual SDB, associated symptoms, and associated neurobehavioral problems after AT; CPAP Adherence and Safety Monitoring |
|
| 6 |
Recruiting
|
Sleep, Cognition and Memory Disorder
| Conditions: |
Sleep Architecture; Sleep Disorders; Cognitive Impairment |
| Interventions: |
Other: 2 night polysomnography; Other: battery of neuropsychological tests; Other: virtual reality test; Other: subjective evaluation of sleep and Somnolence |
| Outcome Measures: |
Polysomnography of night 1; Subjective evaluation of sleep and Somnolence; Evaluation of Memory disorder |
|
| 7 |
Recruiting
|
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
| Conditions: |
Narcolepsy With Cataplexy; Excessive Daytime Sleepiness |
| Interventions: |
Drug: Pitolisant; Drug: Placebo |
| Outcome Measures: |
Measure of anticataplectic efficacy; Excessive Daytime Sleepiness assessment; Safety assessment |
|
| 8 |
Recruiting
|
Amylase and Hypersomnia
| Condition: |
Hypersomnia in Children |
| Intervention: |
Procedure: saliva collection |
| Outcome Measures: |
Determination of the expression and enzymatic activity of salivary amylase.; Measurement of the mean sleep onset latency using the Multiple Sleep Latency Test (MSLT); Measurement of the Somnolence using Epworth and Karolinska scales |
|
| 9 |
Recruiting
|
Palliative Morphine With or Without Concurrent Modafinil
| Conditions: |
Cancer; Pain Palliation; Excessive Sleepiness |
| Interventions: |
Drug: Modafinil; Drug: Placebo |
| Outcome Measures: |
Patient reported sleepiness scores; Mood changes |
|
| 10 |
Unknown †
|
Comparison of RT in Patients With Sleep Apnea With and Without Complaints of Daytime Sleepiness
| Condition: |
Sleep Apnea |
| Intervention: |
|
| Outcome Measure: |
|
|
| 11 |
Recruiting
|
Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy
| Condition: |
Partial Epilepsy |
| Interventions: |
Drug: Lacosamide; Drug: Placebo |
| Outcome Measures: |
Change in Epworth Sleepiness Scale score from Baseline to Visit 4; Change in mean sleep latency on the maintenance of wakefulness test from Baseline to Visit 4. |
|
| 12 |
Unknown †
|
Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep
| Condition: |
COPD |
| Interventions: |
Drug: fluticasone/salmeterol 250/50; Drug: placebo |
| Outcome Measures: |
The aim of this study is to determine the effect of fluticasone/salmeterol on sleep quality in patients with COPD and to compare efficacy of Advair 250 compared to placebo on sleep.; daytime Somnolence |
|
| 13 |
Recruiting
|
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
| Condition: |
Narcolepsy |
| Intervention: |
Drug: Armodafinil |
| Outcome Measures: |
Maximum observed plasma drug concentration (Cmax) by inspection; Time to maximum observed plasma drug concentration (tmax) by inspection; Area under the plasma drug concentration by time curve from time 0 to infinity; Area under the plasma drug concentration by time curve from time 0 to the time of the last measurable drug concentration; Terminal half-life; Terminal elimination rate constant; Apparent total plasma clearance; Apparent volume of distribution; Predicted accumulation ratio; Maximum observed plasma drug concentration (Cmax); Time to maximum observed plasma drug concentration; AUC over 1 dosing interval; AUC 0-t; Observed accumulation ratio; Steady-state accumulation ratio; Mean sleep latency; Clinical Global Impression of Change (CGI-C) |
|
| 14 |
Recruiting
|
Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino
| Condition: |
Multiple Sclerosis |
| Intervention: |
|
| Outcome Measures: |
Fatigue Severity Scale; Modified Fatigue Impact Scale; Fatigue Scale for Motor and Cognitive functions; Visual analogue scale for fatigue; Maintenance of wakefulness test; Epworth Sleepiness Scale; Visual analogue scale for Somnolence; Beck depression inventory II; Mongomery Asberg Depression Rating Scale; Symbol Digit Modalities Test; Paced Auditory Serial Addition Test; Stroop Test |
|
| 15 |
Recruiting
|
Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)
| Condition: |
Narcolepsy |
| Intervention: |
Drug: BF2.649 |
| Outcome Measure: |
Efficacy on EDS as measured by ESS ( Epworth Sleepiness Scale) |
|
| 16 |
Recruiting
|
The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old
| Condition: |
Sleep Deprivation |
| Intervention: |
Behavioral: Partial sleep deprivation allowing 3 h sleep at night |
| Outcome Measure: |
Blood oxygen level-dependent response in amygdala to angry faces (t/z-score from statistical parametric mapping) |
|
| 17 |
Recruiting
|
Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease
| Condition: |
Parkinson's Disease |
| Intervention: |
Other: Light exposure |
| Outcome Measures: |
circadian rhythm of melatonin; Sleep Efficiency; Daytime Somnolence |
|
| 18 |
Recruiting
|
Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease
| Condition: |
Sleep-wake Disturbances in Motor-phase Parkinson`s Disease |
| Intervention: |
Drug: Sodium Oxybate |
| Outcome Measures: |
Objective excessive daytime sleepiness; effect on night-time breathing; Motor function; Subjective quality of nocturnal sleep; Objective quality of nocturnal sleep including breathing indices; Quality of life; Mood; Cognition; Impulse control; Vigilance; Subjective Daytime sleepiness; Sleep wake rhythm; Quality of life for caregivers |
|
| 19 |
Recruiting
|
SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
| Condition: |
Chronic Fatigue Syndrome |
| Interventions: |
Drug: Sodium Oxybate; Other: placebo (fresh potable water) |
| Outcome Measures: |
EEG slow wave activity during sleep; Daytime sleepiness |
|
| 20 |
Recruiting
|
Continuous Positive Airway Pressure and Oral Appliances Treatments in Mild Obstructive Sleep Apnea
| Condition: |
Mild Obstructive Sleep Apnea Syndrome |
| Interventions: |
Device: Continuous Positive Airway Pressure (CPAP); Device: Oral Appliance (BRD) |
| Outcome Measures: |
Excessive Daytime Sleepiness; Evaluations of fatigue.; Evaluation of cognition.; Evaluation of depression.; Evaluation of quality of life.; Evaluation of inflammation.; Evaluation of blood pressure.; Evaluation of sexual dysfunction.; Evaluation of anxiety; Evaluation of metabolism; Evaluation of hormonal alterations.; Evaluation of heart rate variability; Evaluation of endothelial disfunction. |
|
